Innovative Medicine — Sales to customers (Note 9)
Business Segments · Sales to customers (Note 9)Johnson & Johnson Innovative Medicine — Sales to customers (Note 9) increased by 2.4% to $15.56B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.7%, from $14.58B to $15.56B. Over 2 years (FY 2022 to FY 2024), Innovative Medicine — Sales to customers (Note 9) shows relatively stable performance with a 4.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher sales indicate strong market adoption and competitive success of the segment's product portfolio.
Detailed definition
Measures the total revenue generated from external customers by the Innovative Medicine segment. This is the primary top...
Peer comparison
Equivalent to 'Segment Revenue' or 'Net Sales' for pharmaceutical segments at peer companies.
jnj_segment_innovative_medicine_sales_to_customers_note_9Historical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.16B | $12.87B | $13.32B | $13.21B | $13.73B | $13.41B | $13.89B | $13.72B | $13.56B | $14.49B | $14.58B | $14.33B | $13.87B | $15.20B | $15.56B |
| QoQ Change | — | -2.2% | +3.5% | -0.8% | +3.9% | -2.3% | +3.6% | -1.2% | -1.2% | +6.8% | +0.6% | -1.7% | -3.2% | +9.6% | +2.4% |
| YoY Change | — | — | — | — | +4.3% | +4.2% | +4.3% | +3.8% | -1.2% | +8.0% | +4.9% | +4.4% | +2.3% | +4.9% | +6.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported innovative medicine — sales to customers (note 9) of $15.56B in Q3 2025.
- How has Johnson & Johnson's innovative medicine — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's innovative medicine — sales to customers (note 9) increased by 6.7% year-over-year, from $14.58B to $15.56B.
- What is the long-term trend for Johnson & Johnson's innovative medicine — sales to customers (note 9)?
- Over 2 years (2022 to 2024), Johnson & Johnson's innovative medicine — sales to customers (note 9) has grown at a 4.1% compound annual growth rate (CAGR), from $52.56B to $56.96B.
- What does innovative medicine — sales to customers (note 9) mean?
- Total revenue earned from selling products to external customers in the Innovative Medicine segment.